Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT

Core Viewpoint - Altimmune, Inc. is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between August 10, 2023, and June 25, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit was initiated following Altimmune's announcement on June 26, 2025, regarding the topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [2]. - The company's stock price experienced a significant decline of 53.2%, dropping from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, following the disappointing trial results [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until October 6, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].